4-(tert-butoxycarbonylamino-methoxycarbonyl-methyl)-benzoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-(tert-butoxycarbonylamino-methoxycarbonyl-methyl)-benzoic acid
• 英文别名: 4-[2-methoxy-1-[(2-methylpropan-2-yl)oxycarbonylamino]-2-oxoethyl]benzoic acid
• 化学式: C₁₅H₁₉NO₆
• 分子量: 309.319
• InChiKey: YUQVIMQWUBUWCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-氨基吡啶 、 4-(tert-butoxycarbonylamino-methoxycarbonyl-methyl)-benzoic acid 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.5h， 以56%的产率得到tert-butoxycarbonylamino-[4-(pyridin-4-ylcarbamoyl)phenyl]acetic acid methyl ester
  参考文献：
  名称：

  WO2007/6547

  摘要：

  公开号：
• 作为产物：
  描述：

  (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 在 palladium diacetate 、 1,3-双(二苯基膦)丙烷 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(tert-butoxycarbonylamino-methoxycarbonyl-methyl)-benzoic acid
  参考文献：
  名称：

  Suppression of racemization in the carbonylation of amino acid-derived aryl triflates

  摘要：

  The carbonylation of enantiopure phenylglycine-derived aryl triflates was achieved to afford 4-carboxyphenylglycine analogs with high enantiomeric excesses (88 to >99% ee). Amide analogs of phenylglycine were well-tolerated in the hydroxy- and methoxycarbonylation processes, providing efficient access to benzoic acid and ester building blocks. The % ee of the product was dependent on the relative steric bulk of both the amino acid substrate and the requisite amine base, with (Pr2NEt)-Pr-i proving optimal in minimizing product racemization. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2007.04.145

文献信息

• Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors
  申请人：Desarbre Eric

  公开号：US20100056478A1

  公开（公告）日：2010-03-04

  A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).

  一种药物组合物，包括公式（I）的抗生素活性化合物与公式（II）至（XIII）中的β-内酰胺酶抑制剂的组合，对革兰氏阴性菌具有活性，特别是对已经对阿奇霉素、卡鲁莫南和替吉奴等抗生素产生耐药性的细菌具有活性。该组合物还可以包含公式（II）至（XIII）中的另一种β-内酰胺酶抑制剂，特别是公式（V）或公式（VI）的β-内酰胺酶抑制剂。
• Amide derivatives as kinase inhitors
  申请人：Defert Olivier

  公开号：US20100190788A1

  公开（公告）日：2010-07-29

  The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar 1 , Ar 2 , R 1 , R 3 , p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

  本发明涉及新的AGC激酶抑制剂，特别是公式（I）或（II）或其立体异构体，互变异构体，外消旋体，代谢物，前药或前药，盐，水合物或溶剂化物的化合物，其中Ar1，Ar2，R1，R3，p和n具有权利要求中定义的含义。特别地，本发明涉及更具体的ROCK抑制剂，包括这种抑制剂的制剂，特别是药物制剂，并且涉及这种抑制剂在治疗和预防疾病中的用途。
• USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS
  申请人：Basilea Pharmaceutica AG

  公开号：US20150031662A1

  公开（公告）日：2015-01-29

  A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).

  一种药物组合物，包括式(I)的抗生素活性化合物与式(II)至式(XIII)中的一种β-内酰胺酶抑制剂的组合，对革兰氏阴性菌有活性，特别是对已经对阿奇霉素、卡鲁莫纳和替莫纳等抗生素产生耐药性的细菌有活性。该组合物可以包括另一种式(II)至式(XIII)中的β-内酰胺酶抑制剂，特别是式(V)或式(VI)的β-内酰胺酶抑制剂。
• Useful beta-lactamase inhibitors
  申请人：Basilea Pharmaceutica AG

  公开号：EP2308874A1

  公开（公告）日：2011-04-13

  Compounds of the formula II: in which R8 is of the formula Q-(X)r-CO- wherein either a) X = - CH2-, r = 1, Q is a pyridinium group and R7 is -SO3- or -OSO3-; or b) X = -SCH2- and r = 1; wherein Q is e.g. 1,2,3,4-tetrazol-5-yl and R7 is -SO3H or -OSO3H; or c) X = -CH2NH2-, r = 1 and Q is e.g. phenyl or a 5-6-membered heterocycle and R7 is -SO3H or -OSO3H; or d) X = -NH2- and r = 1, wherein Q is e.g. phenyl and R7 is - SO3H or -OSO3H; are beta-lactamase inhibitors. They may be used in combination with monobactams against gram-negative bacteria.

  式 II 的化合物： 其中 R8 为式 Q-(X)r-CO-，其中 a) X = -CH2-，r = 1，Q 为吡啶基，R7 为 -SO3- 或 -OSO3-；或 b) X = -S -，r = 1；其中 Q 为 1，2，3，4-四唑-5-基，R7 为 -SO3H 或 -OSO3H；或 c) X = - NH2-，r = 1，Q 为苯基或 5-6 元杂环，R7 为 -SO3H 或 -OSO3H；或 d) X = -NH2-，r = 1，其中 Q 为 1，2，3，4-四唑-5-基，R7 为 -SO3H 或 -OSO3H。 或 d) X = -NH2-，r = 1，其中 Q 是苯基等，R7 是-SO3H 或-OSO3H。它们可与单内酰胺类药物结合使用，以对付革兰氏阴性菌。
• Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
  申请人：Basilea Pharmaceutica AG

  公开号：EP2484680A1

  公开（公告）日：2012-08-08

  A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula I: with a β-lactamase inhibitor of one of the formulae II to XIII are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae II to XIII, particularly of formula V or formula VI.

  一种药物组合物，由式 I 的抗生素活性化合物组合而成： 与式 II 至式 XIII 之一的 β-内酰胺酶抑制剂的组合物，对革兰氏阴性菌，特别是对抗生素（如阿曲南、卡鲁莫南和替格莫南）产生耐药性的细菌具有活性。可选地，组合物中可包含另一种式 II 至式 XIII 之一的 β-内酰胺酶抑制剂，特别是式 V 或式 VI 的抑制剂。